This Phase 1b study examines the safety and efficacy of parenterally-administered lanicemine
in a parallel-arm, randomized, double-blind, placebo-controlled trial in adult patients
(N=24) with significant PTSD symptoms and elevated anxiety potentiated startle (APS).
Investigator hypothesize that lanicemine (100 mg) displays a normalization of APS following
three infusions over 5 non-consecutive days. If target engagement is demonstrated and the
drug is safe and tolerable in this patient population, investigator will proceed to a larger
POC study.